As of 10:06:35 AM EST. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -1.29 | -1.24 | -7.38 | -5.18 |
| Low Estimate | -1.29 | -1.24 | -7.38 | -5.18 |
| High Estimate | -1.29 | -1.24 | -7.38 | -5.18 |
| Year Ago EPS | -- | -- | -- | -7.38 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | 0.00% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 |
|---|---|---|
| EPS Est. | -1.3 | -0.84 |
| EPS Actual | -4.34 | -1.2 |
| Difference | -3.04 | -0.36 |
| Surprise % | -232.99% | -42.86% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.29 | -1.24 | -7.38 | -5.18 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| TECX | -- | -- | -- | 29.81% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Initiated | Raymond James: Outperform | 11/20/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 11/12/2024 |
| Maintains | Leerink Partners: Outperform to Outperform | 11/11/2024 |
| Initiated | Wells Fargo: Overweight | 8/22/2024 |
| Initiated | Leerink Partners: Outperform | 7/24/2024 |
| Initiated | Piper Sandler: Overweight | 6/26/2024 |
Related Tickers
DNTH Dianthus Therapeutics, Inc.
24.14
+1.39%
OKUR OnKure Therapeutics, Inc.
9.35
-5.17%
SYRE Spyre Therapeutics, Inc.
24.51
+1.60%
QTTB Q32 Bio Inc.
3.6000
-2.70%
NGNE Neurogene Inc.
24.52
+4.30%
MTVA MetaVia Inc.
2.3650
+5.58%
TCRX TScan Therapeutics, Inc.
2.9900
+4.91%
LXEO Lexeo Therapeutics, Inc.
7.02
+1.96%
SLN Silence Therapeutics plc
6.26
-2.94%
ATXS Astria Therapeutics, Inc.
9.85
+3.41%